Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus GG LA801
- Development stage
- Unknown
- Lead developer
- PiLeJe
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus GG LA801 is a specific probiotic strain of *Lactobacillus rhamnosus* GG developed and marketed by Laboratoires PiLeJe. It is formulated as a Food for Special Medical Purposes (FSMP) under the brand name Babybiane Imedia, specifically intended for the nutritional management of acute diarrhea in infants and young children, including cases associated with gastroenteritis, antibiotic therapy, or hospital-acquired infections. The strain functions by enhancing the intestinal barrier through the induction of mucin secretion and tight junction protein expression, competing with pathogens for adhesion sites, and modulating the immune response by increasing mucosal secretory immunoglobulin A (IgA) and stimulating interferon-gamma production. While widely used for acute diarrhea, a clinical trial investigating its use for the prevention of nosocomial diarrhea in children was terminated.
- Brand names
- Babybiane Imedia
- Other names
- Lactobacillus rhamnosus GGLGG
02
Targets
IgA (Immunoglobulin A)IFNG (Interferon gamma)MUC2 (Mucin-2)
Beyond the preview
Go deeper on lactobacillus rhamnosus GG LA801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus GG LA801.